Skip to main content
SpringerLink
Log in

Gatifloxacin

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Gatifloxacin is a novel extended-spectrum fluoroquinolone with improved Gram-positive and anaerobe coverage compared with older agents such as ciprofloxacin. It has good activity (but is slightly less active than ciprofloxacin) against Enterobacteriaceae.

  • ▴ Gatifloxacin is generally 2- to 4-fold more active than ciprofloxacin against staphylococci, streptococci and entero-cocci and 4- to 16-fold more active than ciprofloxacin against anaerobes, including Clostridium and Bacteroides spp.

  • ▴ In comparative clinical trials that included patients with lower respiratory tract, urinary tract, skin and soft tissue or gonococcal infections, clinical cure rates of ≥89% were achieved with oral gatifloxacin 400 mg/day for 7 to 14 days.

  • ▴ Data from a subset of North American patients included in a multinational trial showed that oral gatifloxacin 400 mg/day produced a significantly higher clinical cure rate than cefuroxime axetil 250mg twice daily (89 vs 11%; p = 0.01 ) in patients with acute exacerbations of chronic bronchitis. The clinical efficacy of gatifloxacin was similar to that of clarithromycin or levofloxacin or ceftriaxone (with or without erythromycin) in the treatment of patients with community-acquired pneumonia.

  • ▴ Oral gatifloxacin 400 mg/day showed clinical and bacteriological efficacy similar to that of levofloxacin in patients with skin and soft tissue infections. In patients with urinary tract infections, clinical cure and bacterial eradication rates achieved with a single 400mg oral dose of gatifloxacin were similar to those produced with ciprofloxacin.

  • ▴ In a pooled analysis of tolerability data from trials that included 3021 patients treated with oral gatifloxacin 400 mg/day, the most commonly reported adverse events were nausea (8%), diarrhoea (4%), headache (4%) and dizziness (3%). The drug was reported to be well tolerated. Gatifloxacin does not appear to cause phototoxic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lacreta F, Kaul S, Kollia G, et al. Bioequivalence of 400mg intravenous and oral gatifloxacin in healthy adult subjects [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  2. Jones RN, Biedenbach DJ, Erwin ME, et al. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. J Clin Microbiol 1999; 37(6): 1999–2002

    PubMed  CAS  Google Scholar 

  3. Biedenbach DJ, Beach ML, Jones RN. Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. Diagn Microbiol Infect Dis 1998; 32: 307–11

    Article  PubMed  CAS  Google Scholar 

  4. Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother 1998 Oct; 42: 2678–81

    PubMed  CAS  Google Scholar 

  5. Gradelski E, Kolek B, Bonner D, et al. The mechanisms of antibacterial killing with gatifloxacin (GAT), trovafloxacin (TRO), ciprofloxacin (CIP), and norfloxacin (NOR) [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego

  6. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639–51

    Article  PubMed  CAS  Google Scholar 

  7. Jones RN, Kugler KC, Pfaller MA, et al. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY antimicrobial surveillance program, 1997. Diagn Microbiol Infect Dis 1999; 35: 55–63

    Article  PubMed  CAS  Google Scholar 

  8. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to Gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America from the SENTRY antimicrobial surveillance program, 1997. Clin Inf Dis 1999; 29(3): 595–607

    Article  CAS  Google Scholar 

  9. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to Gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 1999; 33: 283–97

    Article  PubMed  CAS  Google Scholar 

  10. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 1999; 34: 65–72

    Article  PubMed  CAS  Google Scholar 

  11. Naber KG, Hollauer K, Kirchbauer D, et al. In vitro activity of gatifloxacin versus trovafloxacin, BAY 12-8039, ciprofloxacin, fleroxacin and ofloxacin against uropathogens. 2nd European Congress of Chemotherapy and 7th Biennial Conference on Antiinfective Agents and Chemotherapy; 1998 May 10–13: Hamburg

  12. Biedenbach DJ, Croco MAT, Barrett TJ, et al. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates the evaluation of disk diffusion and E test methods. Eur J Clin Microbiol Infect Dis 1999; 18(6): 428–31

    Article  PubMed  CAS  Google Scholar 

  13. Grimm HH. In vitro activity of gatifloxacin in comparison to ciprofloxacin against Gram-positive and Gram-negative pathogens with reduced susceptibility against ciprofloxacin [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, 220

  14. Bauernfeind A, Jungwirth R, Schneider I, et al. Activity of new fluoroquinolones against Burkholderia cepacia and Burkholderia multivorans from cystic fibrosis patients [poster]. The Twelfth Annual North American Cystic Fibrosis Conference 1998: Montreal

  15. Dubois J, St-Pierre C. An in vitro susceptibility study of gatifloxacin against Legionella spp [poster]. Diagn Microbiol Infect Dis 1999: 33(4): 261–266

    Article  PubMed  CAS  Google Scholar 

  16. Miyashita N, Niki Y, Kishimoto T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997 Jun; 41: 1331–4

    PubMed  CAS  Google Scholar 

  17. Ishida K, Kaku M, Irifune K, et al. In vitro and in vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae. J Antimicrob Chemother 1994 Dec; 34: 875–83

    Article  PubMed  CAS  Google Scholar 

  18. Ullmann U, Schubert S, Krausse R. In vitro activity of gatifloxacin, other fluorochinolones, doxycyclin and erythromycin against ureaplasma urealyticum and Mycoplasma hominis [abstract]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 68

    Google Scholar 

  19. Blondeau JM. Expanded activity and utility of the new fluoroquinolones. Clin Ther 1999; 21(1): 3–40

    Article  PubMed  CAS  Google Scholar 

  20. Jones RN, Pfaller MA, Doern GV, et al. Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquinolone, tested against over 23 000 recent clinical isolates from the SENTRY Antimicrobial Surveillance Program, 1997 [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, 225

  21. Doern GV, Pfaller MA, Erwin ME, et al. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada — 1997 results from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 1998; 32: 313–6

    Article  PubMed  CAS  Google Scholar 

  22. Jones RN, Johnson DM, Erwin ME, et al. Antistreptococcal activity of gatifloxacin. Drugs 1999; 58 Suppl. 2: 164–5

    Article  CAS  Google Scholar 

  23. Hoellman DB, Lin G, Jacobs MR, et al. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J Antimicrob Chemother 1999; 43: 645–9

    Article  PubMed  CAS  Google Scholar 

  24. Pfaller MA, Jones RN, Doern GV, et al. Bacterial pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42(7): 1762–70

    PubMed  CAS  Google Scholar 

  25. Jones RN, Pfaller MA, Doern GV, et al. Antimicrobial activity of gatifloxacin tested against 1676 Gram-positive cocci resistant to ciprofloxacin: a multicentre organism sample from North and Latin America. Drugs 1999; 58 Suppl. 2: 162–3

    Article  CAS  Google Scholar 

  26. Jones RN, Beach ML, Pfaller MA, et al. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant Gram-positive cocci isolates from patient infections in North and South America. Diagn Microbiol Infect Dis 1999; 32: 247–52

    Article  Google Scholar 

  27. Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 1993 Jun; 37: 1259–63

    Article  PubMed  CAS  Google Scholar 

  28. Schaumann R, Claros MC, Pleb B, et al. In vitro activity of gatifloxacin against anaerobic bacteria compared with other quinolones and non-quinolone-antimicrobials [poster]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego

  29. Ednie LM, Jacobs MR, Appelbaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother 1998 Sep; 42: 2459–62

    PubMed  CAS  Google Scholar 

  30. Kato N, Kato H, Tanaka-Bandoh K. Comparative in vitro and in vivo activity of AM-1155 against anaerobic bacteria. J Antimicrob Chemother 1997 Nov; 40: 631–7

    Article  PubMed  CAS  Google Scholar 

  31. Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1994 Mar; 38: 594–601

    Article  PubMed  CAS  Google Scholar 

  32. Hosaka M, Yasue T, Fukuda H, et al. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992 Oct; 36: 2108–17

    Article  PubMed  CAS  Google Scholar 

  33. Hirai K, Hosaka M, Wakabayashi E, et al. Antibacterial activity of AM-1155 using an in vitro pharmacokinetic model [abstract]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14: Anaheim, 277

  34. Zinner S, Gilbert D, Simmons K. Activity of simulated oral dosing of gatifloxacin against Streptococcus pneumoniae in an in vitro dynamic model [poster]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego

  35. Bauernfeind A, Eberlein E, Schneider I. Comparative bactericidal kinetics of gatifloxacin (AM 1155) at various dosages in a pharmacodynamic model [abstract]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 69

    Google Scholar 

  36. Pankuch GA, Jacobs MR, Appelbaum PC. Post-antibiotic and post-antibiotic subMIC effect of gatifloxacin against Grampositive and -negative bacteria [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  37. Sato A, Kitazawa H, Hayakawa H, et al. Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model. J Antimicrob Chemother 1997 Feb; 39: 217–22

    Article  PubMed  CAS  Google Scholar 

  38. Drain R, Lamb L, Medina L, et al. Gatifloxacin: efficacy against penicillin-resistant Streptococcus pneumoniae in an experimental murine lung infection model [poster]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, H595

  39. Lutsar I, Friedland IR, Wubbel L, et al. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1998 Oct; 42: 2650–5

    PubMed  CAS  Google Scholar 

  40. Yang H, Drain R, Clark J. Gatifloxacin efficacy against cipro-floxacin-resistant S. pneumoniae and beta-lactamase-positive H. influenzae in an experimental acute otitis media infection model in gerbils [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  41. Ince D, Aras R, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison with ciprofloxacin in Staphylococcus aureus. Drugs 1999; 58 Suppl. 2: 132–3

    Article  CAS  Google Scholar 

  42. Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995 Dec; 39: 2635–40

    Article  PubMed  CAS  Google Scholar 

  43. Grasela D,Lacreta F, Uderman H, et al. A dose-escalation study of the safety, tolerance and pharmacokinetics (PK) of intravenous (IV) gatifloxacin in healthy adult subjects [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  44. Bristol-Myers Squibb Company, Princeton. Data on file. 1998

  45. Shiba K, Sakamoto M, Saito A, et al. Effect of ferrous sulfate, tea and milk on absorption of AM-1155, a 6-fluoro-8-methoxy quinolone in humans [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20: San Francisco, 8

  46. Göhler K, Stahlberg HJ, Guillaume M, et al. Safety, tolerance and food effect after single and multiple oral doses of gatifloxacin, a new fluoroquinolone antibiotic, to healthy Caucasian volunteers [abstract]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 68

    Google Scholar 

  47. LaCreta F, Kollia G, Duncan G, et al. Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers [poster]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, 10

  48. Rolston KV, Gotfried M, Birmingham MC, et al. Penetration of gatifloxacin into lung, bone and skin [abstract]. Bristol-Myers Squibb, Princeton. Data on file. 1999

  49. Kaneko T, Saito J, Ikeda N, et al. Penetration of AM-1155 into female genital tissues [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 353

    Google Scholar 

  50. Naber CK, Steghafner M, Kinzig-Schippers M, et al. Gatifloxacin: plasma and urine concentrations and penetration into prostatic and seminal fluid after single oral administration of 400MG in volunteers [abstract]. 21st International Congress of Chemotherapy; 1999 Jul 4–7: Birmingham

  51. Bristol-Myers Squibb Company, Princeton. Data on file. 1999

  52. Aoki N, Shiba K. Pharmacokinetics of gatifloxacin (AM-1155), a new fluoroquinolone, in elderly patients [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3: 206–7

  53. Kawada Y, Kanimoto Y, Takahashi Y, et al. Pharmacokinetics of gatifloxacin (AM-1155) in patients with impaired renal function [abstract]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 69

    Google Scholar 

  54. Grasela DM, Christofalo B, LaCreta F, et al. Single-dose safety and pharmacokinetics of oral gatifloxacin in subjects with hepatic impairment [poster]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, 9

  55. Olsen SJ, Uderman HD, Kaul S, et al. Pharmacokinetics (PK) of concomitantly administered gatifloxacin and digoxin [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  56. Olsen SJ, Rolan P, Lacreta FP, et al. Lack of effect of gatifloxacin on the pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin [abstract]. Bristol-Myers Squibb, Princeton. Data on file. 1999

  57. Grasela D, Lacreta F, Kollia G, et al. Lack of effect of multiple dose gatifloxacin (GAT) on oral glucose tolerance (OGTT), glucose and insulin homeostasis, and glyburide pharmacokinetics (PK) in patients with type II non-insulin-dependent diabetes mellitus (NIDDM) [abstract]. 39th Interscience Conference on Antimicrobial Agents and Che motherapy; 1999 Sep 26–29: San Francisco

  58. Gajjar DA, Lacreta FP, Kollia GD, et al. Lack of effect of gatifloxacin (GAT) on the pharmacokinetics (PK) of midazolam, a model substrate for cytochrome P450 3A (CYP3A) activity, in healthy adult volunteers [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sept 26–29: San Francisco

  59. Niki Y, Hashiguchi K, Miyashita N, et al. Effect of AM-1155 on serum concentration of theophylline [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18: New Orleans, 112

  60. Stahlberg HJ, Göhler K, Guillame M, et al. Effects of gatifloxacin (GTX) on the pharmacokinetics of theophylline in healthy young volunteers [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 136

    Google Scholar 

  61. Manita S, Toriumi C, Kusajima H, et al. The influence of gatifloxacin (AM-1155) on pharmacokinetics and metabolism of theophylline in rats and humans [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, 5

  62. DeAbate CA, McIvor RA, Di Bartolo C, et al. Gatifloxacin (GAT) 400mg QD vs cefuroxime axetil (CEF) 250mg BID in the treatment of acute exacerbations of chronic bronchitis (AECB) [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  63. DeAbate CA, Fogarty C, Grooms E, et al. Efficacy and safety of gatifloxacin in acute exacerbation of chronic bronchitis [abstract]. Clin Infect Dis 1998 Oct; 27: 953

    Google Scholar 

  64. Ramirez J, Nguyen T-H, Tellier G, et al. Once-daily 400mg oral gatifloxacin (GAT) vs twice-daily 500mg oral clarithromycin (CLA) in the treatment of community-acquired pneumonia [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  65. Dowell M, Mayer H, Anderson A, et al. A randomized, double-blind, multicenter, comparative study of gatifloxacin (GAT) 400mg IV and PO vs ceftriaxone ± erythromycin (CTX + ERY) in treatment of community-acquired pneumonia (CAP) requiring hospitalization [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  66. Lipetz R, Maggiacomo F, Wingert K, et al. A phase II study of oral gatifloxacin (GAT) 400mg QD in the treatment of atypical pneumonia [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  67. Fogarty C, McAdoo M, Paster RZ, et al. Comparison of once-daily gatifloxacin (GAT) 400mg PO for 10 days with twice-daily clarithromycin (CLA) 500mg PO for 14 days in patients with acute maxillary sinusitis: a multicenter phase III study [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  68. Richard GA, Mathew CP, Kirstein JM, et al. Single (400mg) and multiple (200mg QD) dose oral gatifloxacin (GAT) vs multiple (100mg bid) dose oral ciprofloxacin (CIP) in the treatment of acute, uncomplicated urinary tract infection (UTI) in women [abstract]. Bristol-Myers Squibb, Princeton. Data on file. 1999

  69. Cox C, Marbury TC, Pittman WG, et al. A multicenter comparison of gatifloxacin (GAT) 400mg QD vs ciprofloxacin (CIP) 500mg bid in the treatment of complicated urinary tract infection (UTI) and pyelonephritis [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  70. Stoner B, Douglas JM, Martin DH, et al. Single dose gatifloxacin (400 or 600mg) vs single dose ofloxacin (400mg) in the treatment of uncomplicated gonococcal infections [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  71. Tarshis G, Miskin BM, Jones TM, et al. Oral gatifloxacin (GAT) 400mg QD vs oral levofloxacin (LEV) 500mg QD in the treatment of uncomplicated skin and soft tissue infections (SSTI) [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  72. Saito A, Soejima R. The first comparative study with levofloxacin: a double-blind comparative study of gatifloxacin, a new quinolone, and levofloxacin in pneumonia [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, 578

  73. Suzuki K, Katoh S, Horiba M, et al. Gatifloxacin, a newer quinolone derivative in the treatment of chronic bacterial prostatitis [abstract]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 69

    CAS  Google Scholar 

  74. Kawada Y, Saito I, Hirose T, et al. Dose finding study of AM-1155 in complicated urinary tract infections [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 416

    Google Scholar 

  75. Breen J, Skuba K, Grasela D. Safety and tolerability of oral gatifloxacin, a new 8-methoxy fluoroquinolone: overview of clinical data [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29: San Francisco

  76. Ferguson J, McEwen J, Goehler K. A double-blind, placebo- and positive-controlled, randomized study to investigate the phototoxic potential of gatifloxacin, a new fluoroquinolone antibiotic [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27: San Diego, 24–5

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 10, New Zealand

    Caroline M. Perry, Julia A. Barman Balfour & Harriet M. Lamb

Authors
  1. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia A. Barman Balfour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harriet M. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline M. Perry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perry, C.M., Balfour, J.A.B. & Lamb, H.M. Gatifloxacin. Drugs 58, 683–696 (1999). https://doi.org/10.2165/00003495-199958040-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958040-00010

Keywords

Search

Navigation